In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
New Science StartUps and SMEs Financing

Funding The Future: Accelerating The Long Walk To Innovation

Good ideas must be paired with good people

  • Interviews

Executive Summary

In Vivo spoke with two company creators working in the biotech industry about their strategies for seeking new science and their funding philosophy when building the biotechs of tomorrow.

You may also be interested in...



Vaccitech Prepares For IPO, But AZ COVID-19 Vaccine Safety Fears Cloud Launch

The UK biotech aims to raise $100m, but will need to tackle safety concerns to secure a long-term future.

Coming Of Age: Pharma’s Influencer Marketing Matures

Influencer marketing has emerged as a potent tool for many industries and is a sector set to be worth $22bn in its own right by 2025.

Building Out A Blockbuster Franchise: AstraZeneca’s Growth Plans For US Lung Cancer Therapy

Arun Krishna reveals portfolio plans for best-selling therapy Tagrisso, and its other activities to prevent, screen and diagnose lung cancer faster.

Table

View full table

Topics

Related Companies

Tags:
New Science StartUps and SMEs Financing
Latest Headlines

South Korea Sees Pharma Leadership Transition

FDA-EMA Advice Pilot For Complex Generics: What Does Industry Have To Say?

The Sustainability Stakes Are Rising: ‘We Cannot Recycle Our Way Out Of This’

Despite 'Remarkable' ROI On Women’s Health Investments, Money Still Lacking

See All
UsernamePublicRestriction

Register

IV125129

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By